DT-216P2

DRUG2 trials

Sponsors

Design Therapeutics, Inc.

Conditions

Friedreich Ataxia

Phase 1

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

Not yet recruitingNCT06772870

Design Therapeutics, Inc.Friedreich Ataxia

Start: 2025-02-28End: 2025-12-31Target: 36Updated: 2025-02-21

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

RecruitingNCT06874010

Design Therapeutics, Inc.Friedreich Ataxia

Start: 2025-06-30End: 2027-03-31Target: 20Updated: 2025-05-18